News

Mobile health technology to detect AF led to a high rate of false positives in patients with certain cardiac conditions.

The estimated annual percentage change was signficiantly associated with a baseline age-standardized incidence rate of less than 5500 per 100,000 individuals.

The slight benefit could be attributed to a lower than expected adherence to screening requests.

Research suggests disparities between racial and ethnic groups exist among patients with Alzheimer’s disease and related dementias.

Daily administration of AZP-3601 enabled 93% of patients to discontinue standard of care therapy and maintain target mean serum calcium.

A recent study confirmed the safety of tralokinumab with regard to COVID-19 and related vaccinations.

Analyses like the Sickle Cell Data Collection (SCDC) have played prominent roles in establishing new SCD clinics, educating health care providers, guiding new research initiatives, and developing state health care policies.

An increase of 1 microgram/m3 in PM2.5 or 1% in toxic releases equates to an increase in the IBS incidence rate of about 0.02 cases per 100 person-years.

Researchers evaluated the use of IVIG for patients with the rare autoimmune disorder dermatomyositis.

A comprehensive literature review supports the association between sleep disorders and chronic migraine, leading to poor quality of life, loss of workforce and economic burden.

There is no evidence in the value of screening for depression in individuals aged 11 years and younger.

A Mediterranean-type diet was associated with slower GA enlargement in a recent post-hoc analysis.

Multivariable models suggest the leading markers of incident DR and progression to PDR were duration of diabetes and use of insulin.

A recent cohort study of 20 emergency departments assessed allergic contact dermatitis cases.

Catherine Nester, RN, and Dr. Stephen Kingsmore, discuss the pivotal role of newborn screening in diagnosing rare diseases along with the impact that BeginNGS can have on the future of rare disease medicine.

In total, 64.9% of patients who achieved clinical response with ustekinumab during induction were in symptomatic remission after 44 weeks.

Sotatercept added to background therapy demonstrated significant improvement in exercise capacity compared to placebo.

New data indicate a statistically not significant increase in the rate of treatment for PH, but investigators stress its potential clinical importance.

A retrospective analysis of controlled drug dispensation shows conflicting rates of prescriptions to teenagers and young adults.

Treatment initiation was lower among Medicaid and private health insurance recipients aged 18-29 years, compared with patients aged 50-59 years.

The approval indicates the subcutaneous loop diuretic for the at-home treatment of congestion in adults with NYHA Class II/III chronic heart failure.

The risk of primary composite cardiovascular outcomes was reduced by 47%, while the risk of secondary cardiovascular disease outcomes was reduced by 50% in patients with bariatric surgery compared to nonsurgical patients.

New data suggest transparency regarding drug safety regulatory response has not been consistent in recent years.

Children at risk for developing asthma may see benefits from a new screening tool developed to detect symptoms in children age 3 and up.

More than 80 000 pterygium excisions in the IRIS Registry suggest young, male, and publicly insured patients had an elevated risk of reoperation within 5 years.

Both drug classes would improve type 2 diabetes outcomes as first-line agents, but costs would be need to be reduced by at least 70% to be considered cost-effective.

A research team described data regarding the potential of escalating adalimumab doses for certain patients with psoriasis.

In Philadelphia, 28% of the patient population was unscreened, with the factors associated with lower risks of being unscreened generally associated with a higher HCV positivity rate.

The approval, awarded to Alnylam Pharmaceuticals, is based on the results of the ILLUMINATE-C phase 3 trial.

Greater psychological resilience was associated with lower BMI, fewer hospitalizations, and greater mental QOL in the T2D population.